JP6855472B2 - がんを治療するためのｍｄｍ２阻害剤の投与計画 - Google Patents

がんを治療するためのｍｄｍ２阻害剤の投与計画 Download PDF

Info

Publication number
JP6855472B2
JP6855472B2 JP2018520638A JP2018520638A JP6855472B2 JP 6855472 B2 JP6855472 B2 JP 6855472B2 JP 2018520638 A JP2018520638 A JP 2018520638A JP 2018520638 A JP2018520638 A JP 2018520638A JP 6855472 B2 JP6855472 B2 JP 6855472B2
Authority
JP
Japan
Prior art keywords
compound
days
salt
administered
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018520638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531273A6 (ja
JP2018531273A5 (enExample
JP2018531273A (ja
Inventor
ガイチウ アーチー ツェ
ガイチウ アーチー ツェ
シェンリー カイ
シェンリー カイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of JP2018531273A publication Critical patent/JP2018531273A/ja
Publication of JP2018531273A6 publication Critical patent/JP2018531273A6/ja
Publication of JP2018531273A5 publication Critical patent/JP2018531273A5/ja
Priority to JP2021043154A priority Critical patent/JP7192011B2/ja
Application granted granted Critical
Publication of JP6855472B2 publication Critical patent/JP6855472B2/ja
Priority to JP2022195270A priority patent/JP2023025214A/ja
Priority to JP2024139510A priority patent/JP2024164122A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018520638A 2015-10-23 2016-10-21 がんを治療するためのｍｄｍ２阻害剤の投与計画 Active JP6855472B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021043154A JP7192011B2 (ja) 2015-10-23 2021-03-17 がんを治療するためのｍｄｍ２阻害剤の投与計画
JP2022195270A JP2023025214A (ja) 2015-10-23 2022-12-07 がんを治療するためのｍｄｍ２阻害剤の投与計画
JP2024139510A JP2024164122A (ja) 2015-10-23 2024-08-21 がんを治療するためのｍｄｍ２阻害剤の投与計画

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562245632P 2015-10-23 2015-10-23
US62/245,632 2015-10-23
PCT/JP2016/081975 WO2017069289A1 (en) 2015-10-23 2016-10-21 Dosage regimen of mdm2 inhibitor for treating cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021043154A Division JP7192011B2 (ja) 2015-10-23 2021-03-17 がんを治療するためのｍｄｍ２阻害剤の投与計画

Publications (4)

Publication Number Publication Date
JP2018531273A JP2018531273A (ja) 2018-10-25
JP2018531273A6 JP2018531273A6 (ja) 2018-12-13
JP2018531273A5 JP2018531273A5 (enExample) 2019-12-12
JP6855472B2 true JP6855472B2 (ja) 2021-04-07

Family

ID=57349101

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018520638A Active JP6855472B2 (ja) 2015-10-23 2016-10-21 がんを治療するためのｍｄｍ２阻害剤の投与計画
JP2021043154A Active JP7192011B2 (ja) 2015-10-23 2021-03-17 がんを治療するためのｍｄｍ２阻害剤の投与計画
JP2022195270A Pending JP2023025214A (ja) 2015-10-23 2022-12-07 がんを治療するためのｍｄｍ２阻害剤の投与計画
JP2024139510A Pending JP2024164122A (ja) 2015-10-23 2024-08-21 がんを治療するためのｍｄｍ２阻害剤の投与計画

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021043154A Active JP7192011B2 (ja) 2015-10-23 2021-03-17 がんを治療するためのｍｄｍ２阻害剤の投与計画
JP2022195270A Pending JP2023025214A (ja) 2015-10-23 2022-12-07 がんを治療するためのｍｄｍ２阻害剤の投与計画
JP2024139510A Pending JP2024164122A (ja) 2015-10-23 2024-08-21 がんを治療するためのｍｄｍ２阻害剤の投与計画

Country Status (8)

Country Link
US (3) US20180296547A1 (enExample)
EP (1) EP3364972A1 (enExample)
JP (4) JP6855472B2 (enExample)
KR (1) KR20180064540A (enExample)
CN (2) CN113521069A (enExample)
HK (1) HK1253098A1 (enExample)
TW (3) TWI806822B (enExample)
WO (1) WO2017069289A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI697329B (zh) * 2015-04-13 2020-07-01 日商第一三共股份有限公司 血液癌症治療用之醫藥及其用途
HK1253098A1 (zh) * 2015-10-23 2019-06-06 Daiichi Sankyo Company, Limited 用於治疗癌症的mdm2抑制剂的给药方案
US10409015B1 (en) 2015-12-15 2019-09-10 Optomind Inc. Optical receiving device including focusing lens and reflector mounted to housing body and collimating lens mounted to housing cover
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2023016977A1 (en) * 2021-08-09 2023-02-16 Boehringer Ingelheim International Gmbh Oral composition comprising a mdm2-antagonist for cancer therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE470665T1 (de) * 2006-03-22 2010-06-15 Janssen Pharmaceutica Nv Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
EP2059236A2 (en) * 2006-08-21 2009-05-20 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
JP5438008B2 (ja) * 2007-09-21 2014-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
TR201807311T4 (tr) * 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
WO2013101436A1 (en) * 2011-12-07 2013-07-04 Duke University Methods of identifying and using mdm2 inhibitors
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
JP5958208B2 (ja) * 2012-09-10 2016-07-27 凸版印刷株式会社 包装袋
BR112016004593B1 (pt) * 2013-09-04 2022-12-06 Daiichi Sankyo Company, Limited Métodos para reagir um composto, para hidrolisar um composto ou um sal do mesmo, para produzir um composto e para preparar um composto
EP3094746A1 (en) * 2014-01-14 2016-11-23 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
CN107427501B (zh) * 2015-02-20 2023-12-01 第一三共株式会社 通过联合使用治疗癌症的方法
TWI697329B (zh) * 2015-04-13 2020-07-01 日商第一三共股份有限公司 血液癌症治療用之醫藥及其用途
HK1253098A1 (zh) * 2015-10-23 2019-06-06 Daiichi Sankyo Company, Limited 用於治疗癌症的mdm2抑制剂的给药方案

Also Published As

Publication number Publication date
JP2024164122A (ja) 2024-11-26
TW201722427A (zh) 2017-07-01
WO2017069289A1 (en) 2017-04-27
KR20180064540A (ko) 2018-06-14
US20180296547A1 (en) 2018-10-18
CN113521069A (zh) 2021-10-22
US20220071975A1 (en) 2022-03-10
TWI806822B (zh) 2023-07-01
JP7192011B2 (ja) 2022-12-19
HK1253098A1 (zh) 2019-06-06
US11058673B2 (en) 2021-07-13
CN108135892A (zh) 2018-06-08
TW202332444A (zh) 2023-08-16
EP3364972A1 (en) 2018-08-29
TW202515561A (zh) 2025-04-16
JP2021098750A (ja) 2021-07-01
US20190201386A1 (en) 2019-07-04
JP2023025214A (ja) 2023-02-21
JP2018531273A (ja) 2018-10-25

Similar Documents

Publication Publication Date Title
Fu et al. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
US20230146638A1 (en) Treatment of EGFR-Driven Cancer with Fewer Side Effects
JP7192011B2 (ja) がんを治療するためのｍｄｍ２阻害剤の投与計画
JP2023100682A (ja) Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物
KR102644408B1 (ko) 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용
US11395821B2 (en) Treatment of EGFR-driven cancer with fewer side effects
JP2020535173A (ja) Ｈｓｐ９０阻害剤に関係する治療方法
JP2018521058A (ja) ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法
JP2018521058A5 (enExample)
JP6716585B2 (ja) 結腸直腸癌の処置に使用するためのアピリモド
JP2018531273A6 (ja) がんを治療するためのｍｄｍ２阻害剤の投与計画
AU2025202230A1 (en) Biomarkers for sacituzumab govitecan therapy
EP3004396A2 (en) Methods and compositions for the treatment of cancer
JP2019534290A (ja) 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
Hao et al. Current strategies for extensive stage small cell lung cancer beyond first-line therapy
CN115867669A (zh) 监测kras突变的方法
US20240165112A1 (en) Therapy for the treatment of cancer
Turkes Utilising novel therapies in the treatment of gastrointestinal cancers
WO2024263963A2 (en) Compositions comprising antineoplastons and methods of treating head and neck cancer
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
Score Definition and characteristics of elderly patients with lung cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210317

R150 Certificate of patent or registration of utility model

Ref document number: 6855472

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250